N
NewAmsterdam Pharma Company N.V. (NAMS)
NGM – Real Time Price. Currency in USD
29.98
-1.27 (-4.06%)
At close: Mar 27, 2026, 4:00 PM EDT
29.98
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:34 PM EDT

NGM – Real Time Price. Currency in USD
29.98
-1.27 (-4.06%)
At close: Mar 27, 2026, 4:00 PM EDT
29.98
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:34 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 7.88 | 6.05 | 10 | |
| Quick ratio | 7.88 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 103M | 14M | 46M | 23M | 23M |
| Gross Profit | 103M | 14M | 45M | 22M | 22M |
| Operating Income | -1M | -181M | -176M | -226M | -226M |
| Net Income | -23M | -177M | -242M | -204M | -204M |
| EBITDA | -1M | -181M | -176M | -225M | -225M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -63.57 | -40.6 | 1.0 |
| Next quarter | -92.56 | -228.72 | 1.0 |
| Current year | 23.41 | -11.21 | 5.5 |
| Next year | 531.05 | 27.45 | 10 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -90.79 | -4.04 | -2.41 | -24.87 | 1.0 |
| Y/Y | -99.74 | 18.72 | 32.82 | -9.3 | 5.3 |
| 3y average | 28.83 | -234.19 | -30.78 | -486.01 | 3.3 |
| 5y average | 416.9 | 1727.18 | -30.78 | 1252.32 | 7.8 |
| Weighted average score | 4.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $491.3M significantly exceed its total debt $202.0K, ensuring strong financial flexibility
Total current assets $675.7M exceed Total current liabilities $85.8M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$41.0M limits the company's ability to reinvest or pay down debt